This is a large research strand, where we bring together several (bio)medical specialties that share ‘inflammatory mechanisms’ in their etiopathogenesis. Many of the basic and applied research activities are coordinated through a cross-institute Centre for inflammation and Therapeutic Innovation - or CiTI approved by QMUL in 2015.
This has enabled a strategic partnership with UCB Pharma with the Kennedy Institute, for a partnership in the Versus Arthritis Centre of Excellence in Osteo-Arthritis pathogenesis (£1 million). Further, joint research activities with the cardiovascular theme have delivered a BHF Accelerator Award in Cardiac Inflammation.
At present we hold two chairs of Arthritis Research UK, an Experimental Early Arthritis Treatment Centre, several large awards in musculoskeletal, hepatology, multiple sclerosis, gastrointestinal, dermatology and nephrology research. In addition, our inflammation strategy is to work together with bioengineering, nanomedicine and organ-on-a-chip technologies to maximise innovation and cross-fertilisation within Queen Mary University of London, and links with other ongoing research themes, including Dentistry and Trauma as well as diabetes.
The research aims to develop innovative therapeutic strategies, such as nutraceuticals and dietary approaches, human cell-driven target identification and validation.
To accelerate effective and swift drug development, it is important to identify the sub-group of RA patients that will benefit most. Originally funded by the MRC PEAC consortium and then, in this REF period, by the MATURA project (MRC/Versus Arthritis; £5 million joint leadership with Manchester), our stratified medicine programme has secured extension through a €14 million EU award of which ~€1.8m has been to Queen Mary University of London.